Evolution of resistance during clonal expansion

被引:183
作者
Iwasa, Y [1 ]
Nowak, MA
Michor, F
机构
[1] Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan
[2] Harvard Univ, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA
[3] Harvard Univ, Dept Math, Cambridge, MA 02138 USA
[4] Harvard Soc Fellows, Cambridge, MA 02138 USA
关键词
D O I
10.1534/genetics.105.049791
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Acquired drug resistance is a major limitation for cancer therapy Often, one genetic alteration suffices to confer resistance to an otherwise successful therapy. However, little is known about the dynamics of the emergence of resistant tumor cells. In this article, we consider an exponentially growing population starting from one cancer cell that is sensitive to therapy. Sensitive cancer cells can mutate into resistant ones, which have relative fitness a prior to therapy. In the special case of no cell death, our model converges to the one investigated by Luria and Delbruck. We calculate the probability of resistance and the mean number of resistant cells once the cancer has reached detection size M. The probability of resistance is an increasing function of the detection size M times the mutation rate u. If Mu << 1, then the expected number of resistant cells in cancers with resistance is independent Of the mutation rate u and increases with Mill proportion to for advantageous mutants with relative fitness alpha > 1, to In M for neutral mutants (alpha = 1), but converges to an upper limit for deleterious mutants (alpha < 1). Further, the probability of resistance and the average number of resistant Cells increase with the number of cell divisions in the history of the tumor. Hence a tumor subject to high rates of apoptosis will show a higher incidence of resistance than expected on its detection size only.
引用
收藏
页码:2557 / 2566
页数:10
相关论文
共 24 条
  • [1] NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells
    Bentires-Alj, M
    Barbu, V
    Fillet, M
    Chariot, A
    Relic, B
    Jacobs, N
    Gielen, J
    Merville, MP
    Bours, V
    [J]. ONCOGENE, 2003, 22 (01) : 90 - 97
  • [2] Bonhoeffer S, 1997, P ROY SOC B-BIOL SCI, V264, P631
  • [3] Branford S, 2003, BLOOD, V102, p414A
  • [4] Feller W., 1971, An introduction to probability theory and its applications, VII
  • [5] Somatic mosaicism and cancer: inference based on a conditional Luria-Delbruck distribution
    Frank, SA
    [J]. JOURNAL OF THEORETICAL BIOLOGY, 2003, 223 (04) : 405 - 412
  • [6] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    Gorre, ME
    Mohammed, M
    Ellwood, K
    Hsu, N
    Paquette, R
    Rao, PN
    Sawyers, CL
    [J]. SCIENCE, 2001, 293 (5531) : 876 - 880
  • [7] Gupta AK, 2001, CANCER RES, V61, P4278
  • [8] Evolutionary dynamics of invasion and escape
    Iwasa, Y
    Michor, F
    Nowak, MA
    [J]. JOURNAL OF THEORETICAL BIOLOGY, 2004, 226 (02) : 205 - 214
  • [10] Genetic instabilities in human cancers
    Lengauer, C
    Kinzler, KW
    Vogelstein, B
    [J]. NATURE, 1998, 396 (6712) : 643 - 649